Keith W. Pratz, MD¹, Mohamad Cherry, MD, MS², Jessica K. Altman, MD³, Brenda W. Cooper, MD⁴, Jose Carlos Cruz, MD⁵, Joseph G. Jurcic, MD⁶, Mark Levis, MD, PhD¹, Tara Lin, MD⁷, Alexander E. Perl, MD⁸, Nikolai A. Podoltsev, MD, PhD⁹, Gary J. Schiller, MD¹⁰, Jason E. Hill, PhD^11*, Angela James, PhD^11*, Qiaoyang Lu, MS^11* and Ramon V. Tiu, MD^12*

¹Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
²Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK
³Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
⁴University Hospitals, Cleveland Medical Center, Cleveland, OH
⁵Methodist Physician Practices, San Antonio, TX
⁶Columbia University Medical Center, New York, NY
⁷University of Kansas Medical Center, Kansas City, KS
⁸Abramson Comprehensive Cancer Center, University of Pennsylvania, Philadelphia, PA
⁹Yale School of Medicine, New Haven, CT
¹⁰David Geffen School of Medicine at UCLA, Los Angeles, CA
¹¹Astellas Pharma Global Development, Northbrook, IL
¹²Astellas Pharma, Inc., Northbrook, IL

Tapan M. Kadia, MD¹, Gautam Borthakur, MD¹, Naveen Pemmaraju, MD¹, Naval Daver, MD², Courtney D. DiNardo, MD, MSc³, Koji Sasaki, MD⁴, Ghayas C. Issa, MD⁵, Maro Ohanian, DO^1*, Guillermo Montalban Bravo, MD¹, Nicholas J. Short, MD¹, Nitin Jain, MD⁶, Alessandra Ferrajoli, MD¹, Kapil N. Bhalla, MD⁷, Elias Jabbour, MD¹, Rashmi Kanagal-Shamanna, MD⁸, Koichi Takahashi, MD, PhD⁹, Rashmi Malla, RN, BSN^1*, Kelly Marek^1*, Mark Brandt, BS^1*, Uday R. Popat, MD¹⁰, Michael Andreeff, MD, PhD¹¹, Jorge E. Cortes, MD¹², Guillermo Garcia-Manero, MD¹, Marina Konopleva, MD, PhD¹³, Farhad Ravandi, MBBS¹⁴ and Hagop M. Kantarjian, MD¹⁵

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
³Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, MD Anderson Cancer Center, Houston, TX
⁵Department of Leukemia, Universit Y of Texas At Houston, Houston, TX
⁶Associate Professor of Medicine Department of Leukemia The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
⁸Department of Hematopathology, Division of Pathology/Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
⁹Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
¹⁰Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
¹¹Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
¹²Georgia Cancer Center Augusta University, Augusta, GA
¹³Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX
¹⁴Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
¹⁵Department of Leukemia, Professor and Chairman, Department of Leukemia, Samsung Distinguished University Chair in Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Musa Yilmaz, MD¹, Hagop M. Kantarjian, MD², Muharrem Muftuoglu³, Tapan M. Kadia, MD⁴, Marina Konopleva, MD, PhD⁵, Gautam Borthakur, MD¹, Courtney D. DiNardo, MD, MSc⁶, Naveen Pemmaraju, MD¹, Nicholas J. Short, MD¹, Yesid Alvarado, MD⁷, Guillermo Montalban Bravo, MD⁸, Carissa Jurisprudencia^9*, Allison M. Pike, RN^10*, Maro Ohanian, DO^1*, Elias Jabbour, MD¹, Guillermo Garcia-Manero, MD¹, Vivian Ruvolo, MS^11*, Farhad Ravandi, MBBS¹², Michael Andreeff, MD, PhD¹¹ and Naval Daver, MD¹³

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Leukemia, Professor and Chairman, Department of Leukemia, Samsung Distinguished University Chair in Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
³Section of Molecular Hematology and Therapy, Department of Leukemia, MD Anderson Cancer Center , Houston, TX
⁴Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
⁵Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX
⁶Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
⁷Department of Leukemia, MD Anderson Cancer Center, Houston, TX
⁸Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
⁹MD Anderson Cancer Center, Houston, TX
¹⁰The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX
¹¹Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
¹²Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
¹³Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX

Eunice S. Wang, MD¹, Pau Montesinos, MD, PhD^2,3*, Mark D. Minden⁴, Je-Hwan Lee, MD, PhD⁵, Michael Heuser⁶, Tomoki Naoe, MD, PhD⁷, Wen-Chien Chou, MD, PhD⁸, Shufang Liu, PhD^9*, Ruishan Wu, MS^9*, Nisha Philipose, MS^9*, Elizabeth Shima Rich, MD, PhD⁹ and Ramon V. Tiu, MD^10*

¹Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
²CIBERONC, Instituto Carlos III, Madrid, Spain
³Hospital Universitari i Politècnic La Fe, Valencia, Spain
⁴Leukemia Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
⁵Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)
⁶Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
⁷National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
⁸Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
⁹Astellas Pharma Global Development, Northbrook, IL
¹⁰Astellas Pharma, Inc., Northbrook, IL

Tapan M. Kadia, MD¹, Gautam Borthakur, MD¹, Koichi Takahashi, MD, PhD², Courtney D. DiNardo, MD, MSc³, Naval Daver, MD⁴, Naveen Pemmaraju, MD¹, Elias Jabbour, MD¹, Nitin Jain, MD⁵, Nicholas J. Short, MD¹, Wei Qiao, PhD^6*, Lade Adewale^7*, Caitlin R. Rausch, PharmD^8*, Sherry A. Pierce, BSN, BA^1*, Yesid Alvarado, MD⁹, Amin M. Alousi, MD¹⁰, Uday R. Popat, MD¹¹, Issa F. Khouri, MD¹², Guillermo Garcia-Manero, MD¹, Marina Konopleva, MD, PhD¹³, Jorge E. Cortes, MD¹⁴, Farhad Ravandi, MBBS¹⁵ and Hagop M. Kantarjian, MD¹⁶

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
⁵The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston
⁸Pharmacy, MD Anderson Cancer Center, Houston, TX
⁹Department of Leukemia, MD Anderson Cancer Center, Houston, TX
¹⁰Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, TX
¹¹Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
¹²Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
¹³Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX
¹⁴Georgia Cancer Center Augusta University, Augusta, GA
¹⁵Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
¹⁶Department of Leukemia, Professor and Chairman, Department of Leukemia, Samsung Distinguished University Chair in Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Musa Yilmaz, MD¹, Mansour Alfayez^2*, Tapan M. Kadia, MD³, Courtney D. DiNardo, MD, MSc⁴, Gautam Borthakur, MD⁴, Sanam Loghavi, MD⁵, Marina Konopleva, MD, PhD⁶, Rashmi Kanagal-Shamanna, MD⁷, Keyur Patel, MD, PhD^8*, Elias Jabbour, MD⁴, Guillermo Garcia-Manero, MD⁴, Naveen Pemmaraju, MD⁴, Sherry A. Pierce, BSN, BA^4*, Ghayas C. Issa, MD⁹, Nicholas J. Short, MD⁴, Guillermo Montalban Bravo, MD⁴, Koichi Takahashi, MD, PhD¹⁰, Rita Assi, MD^11*, Ahmad S Alotaibi^4*, Michael Andreeff, MD, PhD¹², Jorge E. Cortes, MD¹³, Hagop M. Kantarjian, MD⁸, Farhad Ravandi, MBBS¹⁴ and Naval Daver, MD¹⁵

¹Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
²King Fahad Medical City, Riyadh, Saudi Arabia
³Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX
⁶Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX
⁷Department of Hematopathology, Division of Pathology/Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
⁸University of Texas MD Anderson Cancer Center, Houston, TX
⁹Department of Leukemia, Universit Y of Texas At Houston, Houston, TX
¹⁰Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
¹¹AUB, Beirut, TX, Lebanon
¹²Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
¹³Georgia Cancer Center Augusta University, Augusta, GA
¹⁴Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
¹⁵Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX